



(51) International Patent Classification:

C07D 231/56 (2006.01) *A61P 17/00* (2006.01)
A61K 31/416 (2006.01) *A61P 29/00* (2006.01)
A61P 11/00 (2006.01) *A61P 37/00* (2006.01)

(21) International Application Number:

PCT/GB2012/051503

(22) International Filing Date:

27 June 2012 (27.06.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/502,656 29 June 2011 (29.06.2011) US

(71) Applicant (for all designated States except MG, US): **ASTRAZENECA AB** [SE/SE]; SE-151 85 Södertälje (SE).(71) Applicant (for MG only): **ASTRAZENECA UK LIMITED** [GB/GB]; 2 Kingdom Street, London Greater London W2 6BD (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ANDERSSON, Helen, Ingemo** [SE/SE]; C/o AstraZeneca Intellectual Property, AstraZeneca R&D Södertälje, SE-151 85 Södertälje (SE). **CONWAY, Kelly, Yvonne** [GB/GB]; AstraZeneca, Charter Way, Macclesfield Cheshire SK10 2NA (GB). **QUAYLE, Michael, John** [GB/SE]; AstraZeneca R&D Mölndal, SE-431 Mölndal (SE).(74) Agent: **ASTRAZENECA INTELLECTUAL PROPERTY**; AstraZeneca AB, SE-151 85 Södertälje (SE).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: CRYSTALLINE FORM OF INDAZOLYL AMIDE DERIVATIVES FOR THE TREATMENT GLUCOCORTICOID RECEPTOR MEDIATED DISORDERS



(I)

(57) Abstract: Crystalline forms of 2,2,2-trifluoro-N-[(1R,2S)-1-[1-(4-fluorophenyl)indazol-5-yl]oxy-1-(3-methoxyphenyl)propan-2-yl]acetamide, processes for obtaining them, pharmaceutical intermediates used in their manufacture, pharmaceutical compositions containing them, and their use in medical treatment.